Related Experiment Video

Updated: Aug 9, 2026

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Epsilon protein kinase C as a potential therapeutic target for the ischemic heart

Koichi Inagaki1, Eric Churchill, Daria Mochly-Rosen

  • 1Department of Molecular Pharmacology, Stanford University School of Medicine, CCSR, Room 3145A, 269 Campus Drive Stanford, CA 94305-5174, United States.

Cardiovascular Research
|April 26, 2006
PubMed

Insights

Epsilon protein kinase C (epsilonPKC) plays a key role in protecting the heart from ischemic damage. Research suggests epsilonPKC may offer a therapeutic target for reducing cardiac injury during events like heart attacks.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Ischemic heart disease is a major cause of death globally.
  • Cardiac damage can result from acute myocardial infarction, angina, and scheduled procedures like surgery.
  • Ischemic or pharmacological preconditioning can mitigate myocardial damage.

Purpose of the Study:

  • To review the role of epsilon protein kinase C (epsilonPKC) in cardiac protection.
  • To explore the signal transduction pathways involved in epsilonPKC-mediated cardioprotection.
  • To discuss the potential therapeutic implications of targeting epsilonPKC.

Main Methods:

  • Review of existing animal studies on epsilonPKC and cardioprotection.
  • Analysis of isozyme-specific pharmacological tools to elucidate epsilonPKC pathways.
  • Examination of upstream stimuli and downstream transducers of epsilonPKC.

Main Results:

  • EpsilonPKC is implicated as a critical mediator of preconditioning-induced cardioprotection in animal models.
  • Pharmacological tools have helped identify key components of epsilonPKC signaling pathways.
  • While human data is limited, animal studies indicate a potential therapeutic role for epsilonPKC.

Conclusions:

  • EpsilonPKC is a significant factor in the heart's defense against ischemic injury.
  • Understanding epsilonPKC signaling pathways is crucial for developing new cardioprotective strategies.
  • Targeting epsilonPKC may offer a novel therapeutic approach for managing ischemic heart disease.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...